NCT02120261

Using Saline for Myofascial Pain Syndromes (USAMPS)

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study involves adult patients diagnosed with Myofascial Pain Syndromes (MPS). The purpose of this research study is to determine if there is a therapeutic difference between trigger point injection (TPI) of normal saline and conventional drug mix (local anesthesic + steroid) in treating MPS.

Conditions

• Myofascial Pain Syndrome

Interventions

Type	Name	Description
DRUG	Normal Saline	Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
DRUG	Lidocaine Hydrochloride	Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
DRUG	Triamcinolone acetonide	Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.

Timeline

• Start date: 2014-05-01
• Primary completion: 2016-11-01
• Completion: 2016-11-01
• First posted: 2014-04-22
• Last updated: 2019-05-01
• Results posted: 2019-05-01

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study